Before you can understand how cannabis works, you need to understand the system it works on. The endocannabinoid system (ECS) is one of the most important — and most recently discovered — regulatory systems in the human body. It was only identified in the early 1990s, which is why it's absent from most medical textbooks still in use today. Yet it plays a fundamental role in nearly every major physiological process.
The endocannabinoid system was discovered because scientists were trying to understand how THC — the psychoactive compound in cannabis — produces its effects. In 1988, researchers at the St. Louis University School of Medicine identified the first cannabinoid receptor in the rat brain. In 1990, the human CB1 receptor was cloned. In 1992, Israeli researcher Dr. Raphael Mechoulam's team discovered the first endogenous cannabinoid — a molecule the body produces naturally that binds to the same receptor as THC. They named it anandamide, from the Sanskrit word "ananda," meaning bliss.
The discovery was paradigm-shifting: the body had its own cannabis-like system, operating continuously, long before humans ever used the cannabis plant. Cannabis works because it mimics and modulates this pre-existing system.
Endocannabinoids are lipid-based neurotransmitters produced on demand by cells throughout the body. The two primary endocannabinoids are anandamide (AEA) and 2-arachidonoylglycerol (2-AG). Unlike most neurotransmitters, which are stored in vesicles and released in response to signals, endocannabinoids are synthesized and released immediately when needed — a "retrograde" signaling system that works backward across synapses to regulate neural activity. Anandamide is sometimes called the "bliss molecule" — it produces feelings of well-being and is elevated during exercise (contributing to the "runner's high"). 2-AG is present at much higher concentrations and is the primary ligand for CB2 receptors.
CB1 receptors are the most abundant G-protein coupled receptors in the brain — more numerous than receptors for dopamine, serotonin, or GABA. They are concentrated in the cerebral cortex (cognition), hippocampus (memory), basal ganglia (movement), cerebellum (coordination), and brainstem (pain, nausea). CB1 receptors are also found in peripheral tissues including the liver, adipose tissue, and reproductive organs. CB2 receptors are expressed primarily in immune cells — macrophages, T-cells, B-cells, microglia — and in peripheral tissues including the gut, spleen, bone, and skin. CB2 activation modulates immune function and inflammation without psychoactive effects.
The ECS is tightly regulated by enzymes that break down endocannabinoids after they've served their function. FAAH (fatty acid amide hydrolase) degrades anandamide. MAGL (monoacylglycerol lipase) degrades 2-AG. These enzymes are important therapeutic targets — inhibiting FAAH increases anandamide levels, producing anxiolytic and analgesic effects without the psychoactivity of direct CB1 agonism. CBD works partly by inhibiting FAAH, which is one mechanism behind its anxiolytic effects.
The ECS is fundamentally a homeostatic regulatory system — it helps maintain physiological balance across multiple organ systems. Dr. Vincenzo Di Marzo, one of the leading ECS researchers, summarized its role as: "relax, eat, sleep, forget, and protect." More formally, the ECS regulates:
THC (tetrahydrocannabinol) is a partial agonist at both CB1 and CB2 receptors — it binds to and activates these receptors, mimicking the effects of endocannabinoids but with greater potency and duration. CB1 activation by THC produces analgesia, euphoria, appetite stimulation, memory impairment, and anti-nausea effects. The psychoactive effects of THC are entirely CB1-mediated — CB1 knockout mice show no behavioral response to THC.
CBD's mechanism is more complex and less fully understood. CBD does not directly activate CB1 or CB2 receptors at typical doses. Instead, it works through multiple indirect mechanisms: inhibiting FAAH (increasing anandamide levels), acting as a negative allosteric modulator of CB1 (reducing THC's psychoactive effects), activating TRPV1 channels, inhibiting GPR55 receptors, and modulating serotonin (5-HT1A) and adenosine receptors. This multi-target pharmacology explains CBD's broad therapeutic profile and its ability to counteract some of THC's adverse effects.
Dr. Ethan Russo proposed the "Clinical Endocannabinoid Deficiency" (CED) hypothesis in 2004 — the idea that some chronic conditions may result from insufficient endocannabinoid tone. Conditions proposed to involve CED include migraine, fibromyalgia, and irritable bowel syndrome — all characterized by treatment-resistant pain, altered gut motility, and sleep disturbances. The hypothesis remains controversial but has gained support from studies showing reduced anandamide levels in migraine patients and altered ECS function in fibromyalgia.
Understanding the ECS explains why cannabis has such a broad therapeutic profile — it's modulating a system that regulates nearly every major physiological function. It also explains why individual responses to cannabis vary so dramatically: genetic variations in CB1 and CB2 receptors, FAAH activity, and endocannabinoid production all influence how a person responds to cannabinoids. The ECS is also why cannabis has a remarkably safe toxicological profile — there are virtually no CB1 or CB2 receptors in the brainstem respiratory centers, which is why cannabis overdose, unlike opioid overdose, does not cause respiratory depression.